We advance the field by confirming that PD‐1 and PD‐L1 are discordant across patient‐matched primary and metastatic ccRCC tumors, and provide further evidence that the expression of both markers is higher in primary tumors. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.